Search results
Results From The WOW.Com Content Network
AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on the Nasdaq Stockholm. It is also listed on the American Nasdaq and is a Nasdaq-100 company. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide. [14]
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield [31] and Vaxzevria [1] [32] among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca , [ 33 ] [ 34 ] [ 35 ] using as a vector the modified ...
The latest results from the longer-term follow-ups potentially position AstraZeneca, like rival Pfizer as a future supplier of both COVID-19 vaccines and treatments, with AstraZeneca having said ...
The COVID-19 vaccine, known now as ChAdOx1 nCoV-19 or AZD1222, makes use of this vector, which stimulates an immune response against the coronavirus spike protein. [12] [13] Animal studies began in March 2020, and recruitment of 510 human participants for a phase I/II trial began on 27 March, [17] [18] [19] and the results were presented in ...
European pharma giant AstraZeneca Plc’s (NASDAQ:AZN) Covid vaccine, developed with the University of Oxford, is facing a class action lawsuit alleging its vaccine caused death and serious injury ...
London-listed AstraZeneca began moving into respiratory syncytial virus vaccines and obesity drugs through several deals last year after a slowdown in growth as COVID-19 medicine sales declined.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
A number of COVID‑19 vaccines began to become approved and available at scale in December 2020, with vaccinations beginning to ramp up at scale from the beginning of 2021, among them the Oxford–AstraZeneca COVID‑19 vaccine, based on an adenovirus vector and internally termed AZD1222.